Symposium on the High-quality Development of Mongolian Medicine
10month16On the same day, a high-quality development symposium for Mongolian medicine and the release conference of 'White Paper on the Chinese Mongolian Medicine Market' were held in Beijing. The main guests attending the conference included Liu Ping, Secretary-General of the Chinese National Medical Association; Ulan, Standing Committee Member of the Inner Mongolia Autonomous Region Political Consultative Conference; O·Uliji, President of the Inner Mongolia Mongolian Medicine Engineering Technology Research Institute; Dong Jingcheng, President of the Fudan University Institute of Integrated Traditional Chinese and Western Medicine; Zhou Mingzi, Executive Director for Greater China at Frost & Sullivan; and Xiang Gongwei, Chairman of Aotqi Mongolian Medicine.
At this symposium, Frost & SullivanFrost & SullivanFrost & Sullivan, the market research and consulting firm, has officially released the 'White Paper on the Chinese Herbal Medicine Market' (hereinafter referred to as the 'White Paper'). The white paper points out that recentlyOver the past year, as the influence of ethnic medicines in the global healthcare system has gradually increased, the industry faces dual challenges: integrating modernization with traditional theories. In the development of the ethnic medicine industry, there is still a gap between ethnic medicines and modern medicine in terms of theoretical systems and clinical applications, especially in standardization and internationalization, which requires further efforts. Therefore, promoting the deep integration of ethnic medicines with modern medicine is not only key to enhancing the international competitiveness of ethnic medicines but also an inevitable trend for future development.
Mongolian medicine, as a treasure in the Chinese nation's medical treasure trove, not only carries profound national culture but also forms an independent and complete system of medicine and pharmacy. Together with traditional Chinese medicine, Tibetan medicine, and Uyghur medicine, it constructs China's 'one region, three systems' medical pattern, closely united like pomegranate seeds, jointly maintaining people's health. The white paper details the origin, classification of Mongolian medicine, and its unique pharmacological value. Mongolian medicine occupies an important position in the domestic pharmaceutical market due to its unique cultural background and clinical application value. However, with the continuous evolution of the modern medical system, Mongolian medicine faces challenges from standardized production and sustainable management of medicinal resources. Although the market penetration rate of Mongolian medicine has gradually increased in recent years, there is still much room for improvement in quality standardization and clinical normalization.
In the face of many pain points in the modernization process of Mongolian medicine, the white paper proposes a series of practical solutions. The main current issues in the Mongolian medicine industry include outdated market concepts, an urgent need to accelerate modernization, insufficient evidence-based support for Mongolian medicine theory in modern medicine, and low acceptance of Mongolian medicine by doctors and patients. At the same time, the Mongolian medicine approval process is not perfect, with slow approval of drug numbers, which requires policy attention. The white paper proposesThe proposal aims to introduce modern technological means to enhance the quality control and standardization level of Mongolian medicine production. At the same time, it will increase the clinical application and promotion of Mongolian medicine, gradually promoting the modernization of Mongolian medicine theory standards. These strategies will help Mongolian medicine overcome current industry pain points and pave the way for its sustainable development in the future.
Looking ahead, the market pattern of China's Mongolian medicine industry will continue to move towards internationalization and modernization. The white paper points out that with the advancement of the 'Belt and Road' initiative, the influence of the Mongolian medicine industry in the global market is expected to further expand. The Mongolian medicine industry will enhance its international recognition through cultural dissemination and promote its layout and application in the global market. This will become an important strategic path for future industry development. At the same time, improving the industrial chain, strengthening brand building, and enhancing core competitiveness are all key factors for Mongolian medicine enterprises to remain invincible in global competition.
Xiang Gongwei, Chairman of OTCHIMON Pharmaceutical, proposed at the symposium that Mongolian patent medicine production enterprises must take on the main responsibility for the industrial development of Mongolian patent medicines. Enterprises should focus on market-oriented development strategies and regard marketization as the core competitiveness of Mongolian patent medicine enterprises. In addition, by focusing on the product itself, through the layout of access to medical insurance and essential drug catalogs, they should promote Mongolian medicine to leave Inner Mongolia and ultimately enter the mainstream national pharmaceutical market. At the same time, innovative research and development is key to the high-quality development of Mongolian patent medicines. Enterprises should follow the development path of integrating traditional Chinese, Mongolian, Western medicine, and industry-university-research cooperation, actively promote the post-marketing comprehensive evaluation of core major varieties of Mongolian patent medicines, strengthen the innovative research and development of Mongolian patent medicines and the standardization of Mongolian medicine theory, so as to better serve the life and health of the general public.
The participants in the symposium unanimously agreed that the high-quality development of Mongolian medicine requires efforts in multiple aspects. These include policy incentives and regulatory intervention, technological upgrading and capability innovation, the commercialization and transformation capabilities of technology, the construction of an industrial chain ecosystem, and stable raw material sources.
The convening of the Symposium on the High-quality Development of Mongolian Medicine provides an important platform for the inheritance and innovation of Mongolian medicine. The 'White Paper on the Chinese Mongolian Medicine Market' will also continue to play its guiding and instructive role, providing new impetus for the development of Mongolian medicine.
